Overview

* Tandem Diabetes Q2 sales rise to $240.7 mln, achieving record sales

* Adjusted operating loss missed analyst expectations, per LSEG data

* Co expects to reach $1 bln in sales for full year 2025

Outlook

* Tandem expects 2025 sales to reach $1 bln worldwide

* Company forecasts $700 mln U.S. sales in 2025

* Company anticipates $300 mln sales outside U.S. in 2025

* Tandem sees 2025 adj EBITDA margin at negative 5%

Result Drivers

* RECORD SALES - Achieved record second quarter sales in the U.S. and internationally

* U.S. PUMP SHIPMENTS - Increased U.S. pump shipments contributed to sales growth, per CEO John Sheridan

* TECHNOLOGY INTEGRATION - Early access program for t:slim X2 with Control-IQ+ technology integrated with Abbott's FreeStyle Libre 3 Plus sensor initiated

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss -$32.40 -$27 mln

Adjusted mln (17

Net Analysts

Income )

Q2 Net -$52.40

Income mln

Q2 Gross 52.0%

Margin

Q2 Miss -$31.90 -$26.90

Adjusted mln mln (18

Operatin Analysts

g income )

Q2 -$51.80

Operatin mln

g income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 11 "strong buy" or "buy", 11 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Tandem Diabetes Care Inc ( TNDM ) is $27.00, about 43.9% above its August 5 closing price of $15.15

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)